tldrdailynews.com logo
Tag

Kras Mutation

All articles tagged with #kras mutation

Charleston Gains Access to Breakthrough KRAS Pancreatic Cancer Drug
health20 days ago

Charleston Gains Access to Breakthrough KRAS Pancreatic Cancer Drug

Charleston-area patients with metastatic pancreatic cancer are receiving daraxonrasib, a KRAS-targeted drug that showed in Phase 3 trials to roughly double median survival (about 13.2 months versus 6.6 with chemotherapy) via an expanded-access program before FDA approval. Terri Truere became the first local patient treated at Roper St. Francis Cancer Center, a development clinicians say could improve targeting of the KRAS mutation and potentially expand surgical options, though the drug carries notable side effects such as mouth sores, sore throat and rash. The rollout offers optimism for pancreatic cancer treatment and for next-generation KRAS therapies.

via Post and Courier|
#charleston#daraxonrasib#expanded-access
KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients
health20 days ago

KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients

A Phase 3 trial showed daraxonrasib, a KRAS-targeting therapy for metastatic pancreatic cancer, nearly doubles median survival (about 13.2 months vs 6.6) and is moving into expanded-access programs, with Terri Truere in Charleston among the first patients in the area to receive it ahead of FDA approval. The drug is not yet approved, but more SC sites are preparing to offer it; it carries notable side effects such as mouth sores and rash, and access remains limited. Doctors see promise that KRAS targeting could improve outcomes and potentially expand surgical eligibility in some patients.

via Yahoo|
#charleston#daraxonrasib#expanded-access
Promising KRAS-targeting drug daraxonrasib doubles survival in late-stage pancreatic cancer
health1 month ago

Promising KRAS-targeting drug daraxonrasib doubles survival in late-stage pancreatic cancer

Daraxonrasib, a KRAS-targeting drug for stage 4 pancreatic cancer, doubled survival in trials (6.7 to 13.2 months) and is being provided through an Extended Access Program ahead of FDA approval; nine Intermountain Health patients are enrolled. It is not a cure and carries side effects like rash, diarrhea, and mouth sores.

via ksl.com|
#daraxonrasib#extended-access-program#fda-approval
KRAS-targeting drug doubles survival in pancreatic cancer, fueling hope for broader use
health3 months ago

KRAS-targeting drug doubles survival in pancreatic cancer, fueling hope for broader use

Phase 3 results show the KRAS-targeting drug daraxonrasib doubles median survival in advanced pancreatic cancer (13.2 months vs 6.7 with chemotherapy), with FDA fast-track and expanded-access moves under way. The oral drug works by binding the KRAS-driven protein via cyclophilin A and appears less toxic than chemo, prompting optimism about its use in other KRAS-driven cancers, though it is not a cure and researchers are exploring where it fits in treatment sequences.

via NBC News|
#clinical-trial#daraxonrasib#fda-approval
health3 years ago

"New Vaccine Offers Hope for Treating Deadly Forms of Cancer"

An off-the-shelf cancer vaccine has shown potential to prevent relapse in patients with pancreatic and colon cancer caused by the KRAS mutation, which accounts for up to 90% of the disease. The vaccine uses peptides to bind to the protein albumin, creating white blood cells that help fight off cancer markers present in the patients’ blood. The vaccine was 100% effective at creating an immune response in patients and could help lower cancer biomarkers. The vaccine won't have to be customized to each patient, making it more readily available and less expensive. Larger studies are needed to confirm its efficacy.

via msnNOW|
#cancer#colon-cancer#health
health3 years ago

New Cancer Vaccine Shows Promise in Treating Deadliest Forms: Study

An off-the-shelf cancer vaccine has shown potential to prevent relapse in patients with pancreatic and colon cancer caused by the KRAS mutation, which accounts for up to 90% of the disease. The vaccine uses peptides to bind to the protein albumin, creating white blood cells that help fight off cancer markers present in the patients’ blood. The vaccine was 100% effective at creating an immune response in patients and could help lower cancer biomarkers. The vaccine won't have to be customized to each patient, making it more readily available and less expensive. Larger studies are needed to confirm its efficacy.

via msnNOW|
#cancer#colon-cancer#health
New Cancer Vaccine Shows Promise in Treating Deadly Forms and Preventing Relapse
health3 years ago

New Cancer Vaccine Shows Promise in Treating Deadly Forms and Preventing Relapse

An off-the-shelf cancer vaccine developed by Elicio Therapeutics has shown potential to lower the risk of relapse in patients with colon and pancreatic cancers caused by the KRAS mutation, which accounts for up to 90% of cases. In an early trial, the vaccine was found to be safe and feasible, and could improve survival rates for these two deadly cancers. Unlike other experimental cancer vaccines, this vaccine does not need to be customized to each patient, making it more readily available and less expensive. The vaccine uses peptides to bind to the protein albumin, which then travels to the lymph nodes and creates white blood cells to fight off cancer markers found in the patients' blood.

via Daily Mail|
#cancer#colon-cancer#health